FDA approves more menopause-therapy label changes while monitoring patch supply
Three additional estradiol patch products received revised boxed warnings as manufacturers expand output amid localized availability problems.
Three more patch products received revised labeling
The Food and Drug Administration has approved labeling changes for three additional menopausal hormone therapy products from two applicants. The products are estradiol transdermal patches. The revised boxed-warning sections remove statements concerning cardiovascular disease, breast cancer and probable dementia, extending an effort that covered six products in February.
A boxed warning is the agency's most prominent drug-safety warning. Removing specified statements from that box does not mean that hormone therapy is risk-free or appropriate for every patient. FDA continues to provide cardiovascular and breast-cancer information elsewhere in labeling, and systemic estrogen-alone products retain a boxed warning concerning endometrial cancer.
FDA began asking manufacturers for proposed revisions in November 2025 after reviewing scientific literature, utilization information and public input. The agency says 29 companies have submitted labeling proposals. Each product's approved prescribing information, rather than a class-wide announcement, is the controlling source for its current warnings and instructions.
Supply work is proceeding alongside label review
FDA also reported continued work with all six manufacturers of approved estradiol transdermal patches. Demand has risen, and patients have reported difficulty finding their usual brand or strength in some locations. The agency says it is not aware of an imminent nationwide shortage, but local availability can vary by pharmacy, dose and once- or twice-weekly formulation.
Manufacturers have added shifts, expanded capacity, increased batch sizes and installed specialized equipment. FDA says overall market output has doubled during the past 12 months. That national production figure does not guarantee that every pharmacy has every product, because manufacturing, distribution and local inventory move on different schedules.
The agency is also using regulatory tools for production changes and certain compounding circumstances. Compounded medicine is not automatically interchangeable with an FDA-approved product, and the rules differ between outsourcing facilities and patient-specific pharmacy compounding. Patients should use a pharmacist or prescriber to evaluate an appropriate alternative.
Treatment decisions remain individualized
Menopausal hormone therapies include systemic estrogen, combined estrogen and progestogen, progestogen alone in some treatment plans, and local vaginal estrogen. Different formulations address different symptoms and carry different considerations. A label revision for an estradiol patch should not be generalized to every hormone product.
FDA advises patients who cannot find their usual patch to contact the pharmacy and the prescribing clinician and not stop or change treatment without professional guidance. A pharmacist may be able to locate an equivalent approved product, while the clinician can consider a different strength, formulation or route based on the patient's history.
The agency maintains a product list linking to updated prescribing information. That list and the individual label offer more useful evidence than a simplified claim that warnings were either fully removed or unchanged. The practical update is twofold: three more patch labels have changed, and FDA is monitoring a supply system responding to increased demand.